Korean J Obstet Gynecol.  2005 Jun;48(6):1476-1483.

The relationship between calcitonin receptor gene AluI polymorphism, bone mineral density and bone responsiveness to hormone replacement therapy in postmenopausal Korean women

• Kim JG
• Ku SY
• Jee BC
• Suh CS
• Kim SH
• Choi YM
• Moon SY

Abstract

OBJECTIVE
To evaluate the relationship between the calcitonin receptor (CTR) gene AluI polymorphism, serum calcitonin levels, bone mineral density (BMD) and bone responsiveness to hormone replacement therapy (HRT).
METHODS
The CTR AluI polymorphism were determined by restriction fragment length polymorphism (RFLP) in 433 postmenopausal Korean women. Among these women, 306 women received sequential HRT for 1 year. Serum bone alkaline phosphatase, CrossLaps, osteocalcin and calcitonin levels were measured by immunoassay and BMD at the lumbar spine and proximal femur by dual energy X-ray absorptiometry before and after HRT of 1 year.
RESULTS
The CTR genotype frequencies were 81.3% for CC, 17.5% for CT, and 1.2% for TT. No significant differences in BMD at the lumbar spine and proximal femur and their annual percentage changes after HRT were noted among CTR genotypes. There were no significant differences in the levels of calcitonin or bone turnover markers and their 6 month percentage changes after HRT among CTR genotypes. The CTR genotypes were not distributed differently between HRT-responders and HRT-nonresponders (women who lose more than 3% of bone mass per year) or between women with normal BMD and women with low bone mass.
CONCLUSION
The CTR AluI polymorphism is not associated with BMD and bone responsiveness to HRT in Korean women.

Keyword

Postmenopausal women; Calcitonin receptor; AluI polymorphism; BMD; HRT

MeSH Terms

Absorptiometry, Photon
Alkaline Phosphatase
Bone Density*
Calcitonin*
Female
Femur
Genotype
Hormone Replacement Therapy*
Humans
Immunoassay
Osteocalcin
Polymorphism, Restriction Fragment Length
Receptors, Calcitonin*
Spine
Alkaline Phosphatase
Calcitonin
Osteocalcin
Receptors, Calcitonin